Urinary trypsin inhibitor reduced inflammatory response after stent injury in minipig

Pathology Research and Practice

Volumn 208, Issue 6, 2012, Pages 344-349

  Kong, J Y ^a   Wang, T Q ^a   Jiang, G H ^a   Li, L ^a   Wang, F P ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Restenosis; Stent; Urinary trypsin inhibitor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; ULINASTATIN;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN-STENT RESTENOSIS; INFLAMMATION; INJURY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MINIPIG; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; STENT INJURY;

ANIMALS; CONSTRICTION, PATHOLOGIC; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; INFLAMMATION; NEOINTIMA; STENTS; SWINE; SWINE, MINIATURE; TRYPSIN INHIBITORS;

EID: 84861675885     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.03.008     Document Type: Article

References (36)

1. Akashi K., Ishimaru T., Shibuya T., Harada M., Niho Y. Human urinary proteinase inhibitor in the treatment of P carinii pneumonia. Chest 1991, 99:1055-1056.
2. Ambiru S., Miyazaki M., Sasada K., Ito H., Kimura F., Nakagawa K., Shimizu H., Ando K., Nakajima N. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Dig. Surg. 2000, 17:337-343.
3. Aosasa S., Ono S., Mochizuki H., Tsujimoto H., Ueno C., Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001, 15:101-105.
4. Autieri M.V., Yue T.L., Ferstein G.Z., Ohlstein E. Antisense oligonucleotide to the P65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem. Biophys. Res. Commun. 1995, 213:827-836.
5. Biasucci L.M., Vitelli A., Liuzzo G., Altamura S., Caligiuri G., Monaco C., Rebuzzi A.G., Ciliberto G., Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94:874-877.
6. Cilingiroglu M., Elliott J., Patel D., Tio F., Matthews H., McCasland M., Trauthen B., Elicker J., Bailey S.R. Long-term effects of novel biolimus eluting DEVAXAXXESS plus nitinol self-expanding stent in a porcine coronary model. Catheter. Cardiovasc. Interv. 2006, 68:271-279.
7. Cipollone F., Marini M., Fazia M., Pini B., Iezzi A., Reale M., Paloscia L., Materazzo G., D'Annunzio E., Conti P., Chiarelli F., Cuccurullo F., Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler. Thromb. Vasc. Biol. 2001, 21:327-334.
8. Damas P., Canivet J.L., de Groote D., Vrindts Y., Albert A., Franchimont P., Lamy M. Sepsis and serum cytokine concentrations. Crit. Care Med. 1997, 25:405-412.
9. Gaspardone A., Versaci F. Coronary stenting and inflammation. Am. J. Cardiol. 2005, 96:65L-70L.
10. Gogo P.B., Schneider D.J., Watkins M.W., Terrien E.F., Sobel B.E., Dauerman H.L. Systemic inflammation after drug-eluting stent placement. J. Thromb. Thrombolysis 2005, 19:87-92.
11. Jiang Y.F., Wang W.W., Ye W.L., Ni Y.F., Li J., Chen X.L., Jin S.W., Lian Q.Q. Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases. Zhonghua Yi Xue Za Zhi. 2008, 88:2893-2897.
12. Karthikeyan G., Bhargava B. Prevention of restenosis after coronary angioplasty. Curr. Opin. Cardiol. 2004, 19:500-509.
13. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial Injury to neointimal hyperplasia. J. Am. Coll. Cardiol. 1998, 31:224-230.
14. Kozinski M., Krzewina-Kowalska A., Kubica J., Zbikowska-Gotz M., Dymek G., Piasecki R., Sukiennik A., Grzesk G., Bogdan M., Chojnicki M., Dziedziczko A., Sypniewska G. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis - comparison with stable and unstable angina. Inflamm. Res. 2005, 54:187-193.
15. Li J.J. Inflammatory response, drug-eluting stent and restenosis. Chin. Med. J. (Engl.) 2008, 121:566-572.
16. Li J.J., Nie S.P., Zhang C.Y., Gao Z., Zheng X., Guo Y.L. Is inflammation a contributor for coronary stent restenosis?. Med. Hypotheses 2007, 68:945-951.
17. Li J.J., Xu B., Yang Y.J., Ma W.H., Chen J.L., Qiao S.B., Qin X.W., Yao M., Liu H.B., Wu Y.J., Yuan J.Q., Chen J., You S.J., Dai J., Xia R., Gao R.L. A comparison of angiographic and clinical outcomes after sirolimus-eluting versus paclitaxel-eluting stents for the treatment of in-stent restenosis. Chin. Med. J. (Engl.) 2006, 119:1059-1064.
18. Lin S.D., Endo R., Sato A., Takikawa Y., Shirakawa K., Suzuki K. Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis. J. Gastroenterol. Hepatol. 2002, 17:140-147.
19. Liuzzo G., Buffon A., Biasucci L.M., Gallimore J.R., Caligiuri G., Vitelli A., Altamura S., Ciliberto G., Rebuzzi A.G., Crea F., Pepys M.B., Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998, 98:2370-2376.
20. Lowe H.C., Oesterle S.N., Khachigian L.M. Coronary in-stent restenosis: current status and future strategies. J. Am. Coll. Cardiol. 2002, 39:183-193.
21. Nakatani K., Takeshita S., Tsujimoto H., Kawamura Y., Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J. Leukoc. Biol. 2001, 69:241-247.
22. Oshima S., Ogawa H., Hokimoto S., Nakamura S., Noda K., Saito T., Soejima H., Takazoe K., Ishibashi F., Yasue H. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn. Circ. J. 2001, 65:261-264.
23. Peters S. Comparison of efficacy of low- (80mg/day) and high- (160-320mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am. J. Cardiovasc. Drugs 2008, 8:83-87.
24. Peters S., Götting B., Trümmel M., Rust H., Brattström A. Valsartan for prevention of restenosis after stenting of type B2/C lesion: the VAL-PREST trial. J. Invasive Cardiol. 2001, 13:93-97.
25. Petronio A.S., Amoroso G., Limbruno U., Papini B., De Carlo M., Micheli A., Ciabatti N., Mariani M. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am. Heart J. 2005, 149:520-526.
26. Prati F., Imola F., Corvo P., Cernigliaro C., Fouadi T., Ramazzotti V., Manzoli A., Pappalardo A., Cera M. The RESTART project: high-dose atorvastatin helps control RESTenosis AfteR sTenting procedures at high risk for restenosis. Results from a prospective study and a matched control group comparison. EuroIntervention 2007, 3:89-94.
27. Kanai T., Ishiwata T., Kobayashi T., Sato H., Takizawa M., Kawamura Y., Tsujimoto H., Nakatani K., Ishibashi N., Nishiyama M., Hatai Y., Asano Y., Kobayashi T., Takeshita S., Nonoyama S. With Kawasaki disease: a retrospective study ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients. Circulation 2011, 124:2822-2828.
28. Sato N., Murakami K., Ishida K., Ikeda K., Saito K. Pulmonary hypertension and polymorphonuclear leukocyte elastase after esophageal cancer operations. Ann. Thorac. Surg. 1991, 51:754-758.
29. Schwartz R.S., Huber K.C., Murphy J.G., Edwards W.D., Camrud A.R., Vlietstra R.E., Holmes D.R. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J. Am. Coll. Cardiol. 1992, 19:267-274.
30. Senzaki H., Masutani S., Kobayashi J., Kobayashi T., Nakano H., Nagasaka H., Sasaki N., Asano H., Kyo S., Yokote Y. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001, 104:860-863.
31. Suzuki T., Ishiwata S., Hasegawa K., Yamamoto K., Yamazaki T. Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis. Heart 2000, 83:578.
32. Tani T., Abe H., Endo Y., Hanasawa K., Kodama M. Effects of a urinary trypsin inhibitor on acute circulatory insufficiency after surgical operation. Am. J. Surg. 1998, 175:142-145.
33. Versaci F., Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron. Artery Dis. 2004, 15:307-311.
34. Walter D.H., Schachinger V., Elsner M., Mach S., Auch-Schwelk W., Zeiher A.M. Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol. 2000, 85:962-968.
35. Welt F.G., Rogers C. Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1769-1776.
36. Zhou Q., Wang G., Gao C., Chen T. Effect of ulinastatin on perioperative inflammatory response to coronary artery bypass grafting with cardiopulmonary bypass. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010, 35:107-110.